Genenta Science S.p.A. - American Depositary Shares (GNTA)

Competitors to Genenta Science S.p.A. - American Depositary Shares (GNTA)

Adaptimmune Therapeutics PLC 

Adaptimmune specializes in T-cell therapy aimed at treating cancer, which overlaps with Genenta Science's innovative approach using genetically modified immune cells. While both companies are in the CAR-T space, Adaptimmune holds a strong position with its specific focus on targeting cancer antigens, potentially offering more established outcomes and partnerships that can lead to a competitive edge.

Bluebird Bio, Inc. 

Bluebird Bio develops gene therapies primarily for genetic diseases and cancer, intersecting with Genenta Science’s target market. While Bluebird has a broader portfolio and established clinical data, Genenta's focus on a specific cancer treatment may allow it to carve a niche within a targeted patient population, thus enabling competition based on direct therapeutic focus.

CRISPR Therapeutics AG 

CRISPR Therapeutics is at the forefront of gene editing technologies, providing a wide array of applications in gene therapy for various diseases, including cancer. Given CRISPR's technologically advanced methodologies and partnerships, it holds a significant competitive advantage in research and development, although Genenta's novel approach to cancer therapy via genetic modifications offers unique differentiation.

OncoSec Medical Incorporated

OncoSec Medical is developing intratumoral therapies that stimulate the immune system to fight cancer, posing competition to Genenta's immune-oncology focus. While Genenta harnesses viral vectors for gene delivery, OncoSec's innovative techniques aim to enhance local tumor response, making them a notable competitor in terms of treatment modality and trial outcomes.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics focuses on gene-edited therapies, similar to Genenta Science's approach using gene therapies for cancer treatment. Both companies aim to harness the power of genetics and cell therapy, but Sangamo has a broader pipeline including therapies for hemophilia and beta thalassemia, which may provide a competitive edge in terms of market reach and partnerships.